Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer
Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. : Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Out of 28...
Gespeichert in:
| Veröffentlicht in: | Future oncology (London, England) England), 2020-07, Vol.16 (19), p.1371-1384 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1384 |
|---|---|
| container_issue | 19 |
| container_start_page | 1371 |
| container_title | Future oncology (London, England) |
| container_volume | 16 |
| creator | Kuppen, Malou Cp Westgeest, Hans M van der Doelen, Maarten J van den Eertwegh, Alphonsus Jm Coenen, Jules Llm Aben, Katja Kh van den Bergh, Alphons Cm Bergman, Andries M den Bosch, Joan van Celik, Filiz Hendriks, Mathijs P Lavalaye, Jules der Meer, Saskia van Polee, Marco B Somford, Diederik M van Oort, Inge M Uyl-de Groot, Carin A Gerritsen, Winald R |
| description | Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity.
: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223.
Out of 285 patients, 49% received Ra-223 in line ≥3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line ≥3 (HR: 3.267; 95% CI: 1.689–6.317; p < 0.01) remained associated with worse OS.
: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014–2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events. |
| doi_str_mv | 10.2217/fon-2020-0039 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2408192252</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2408192252</sourcerecordid><originalsourceid>FETCH-LOGICAL-c476t-8d3025a9ad77025fb9fbec2c539e8d2532505ffc60965ff984abfd41463cc6703</originalsourceid><addsrcrecordid>eNp1kE1rHSEUhqW0NB_tstsidNONqV-j4zKEtAkEAqFdW68eqWFmTHSG0H_fc7lJF4Wuzqvn8agPIR8EP5NS2C-5LkxyyRnnyr0ix8JqzUbFxWvM2jpmjNNH5KT3e861VQN_S46U1MYZbo7JzzsIE3uqbUq0bmusM3RaM20hlW1mUiqaSvw11VYS0FwbnWENfQ1riTRiaJjqQhv0grvLSh9a3bcBu0uE9o68yWHq8P65npIfXy-_X1yxm9tv1xfnNyxqa1Y2JsXlEFxI1mLIO5d3EGUclIMxyUHJgQ85R8OdwepGHXY5aaGNitFYrk7J58NcvP9xg776ufQI0xQWqFv3UvNROCkHieinf9D7urUFX4eUVVrbUQik2IGK-KHeIPuHVubQfnvB_V69R_V-r97v1SP_8Xnqtpsh_aVfXCPgDkDe1g19xQIoyB9WeKLEssB_hv8Byd2SyQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2473447811</pqid></control><display><type>article</type><title>Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer</title><source>MEDLINE</source><source>PubMed Central</source><creator>Kuppen, Malou Cp ; Westgeest, Hans M ; van der Doelen, Maarten J ; van den Eertwegh, Alphonsus Jm ; Coenen, Jules Llm ; Aben, Katja Kh ; van den Bergh, Alphons Cm ; Bergman, Andries M ; den Bosch, Joan van ; Celik, Filiz ; Hendriks, Mathijs P ; Lavalaye, Jules ; der Meer, Saskia van ; Polee, Marco B ; Somford, Diederik M ; van Oort, Inge M ; Uyl-de Groot, Carin A ; Gerritsen, Winald R</creator><creatorcontrib>Kuppen, Malou Cp ; Westgeest, Hans M ; van der Doelen, Maarten J ; van den Eertwegh, Alphonsus Jm ; Coenen, Jules Llm ; Aben, Katja Kh ; van den Bergh, Alphons Cm ; Bergman, Andries M ; den Bosch, Joan van ; Celik, Filiz ; Hendriks, Mathijs P ; Lavalaye, Jules ; der Meer, Saskia van ; Polee, Marco B ; Somford, Diederik M ; van Oort, Inge M ; Uyl-de Groot, Carin A ; Gerritsen, Winald R</creatorcontrib><description>Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity.
: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223.
Out of 285 patients, 49% received Ra-223 in line ≥3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line ≥3 (HR: 3.267; 95% CI: 1.689–6.317; p < 0.01) remained associated with worse OS.
: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014–2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon-2020-0039</identifier><identifier>PMID: 32469606</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Aged ; Aged, 80 and over ; Antineoplastic Agents - administration & dosage ; Bone Neoplasms - metabolism ; Bone Neoplasms - radiotherapy ; Bone Neoplasms - secondary ; Cancer therapies ; Databases, Factual ; Drug Administration Schedule ; Hemoglobin ; Humans ; Lymphatic system ; Male ; Metastasis ; metastatic castration-resistant prostate cancer ; Middle Aged ; Patients ; Prostate cancer ; Prostatic Neoplasms, Castration-Resistant - metabolism ; Prostatic Neoplasms, Castration-Resistant - pathology ; Prostatic Neoplasms, Castration-Resistant - radiotherapy ; Radioisotopes - administration & dosage ; Radium - administration & dosage ; radium-223 ; real-world outcomes ; Retrospective Studies ; sequencing ; skeletal-related events ; survival ; Survival Rate ; Treatment Outcome</subject><ispartof>Future oncology (London, England), 2020-07, Vol.16 (19), p.1371-1384</ispartof><rights>2020 Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd Jul 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c476t-8d3025a9ad77025fb9fbec2c539e8d2532505ffc60965ff984abfd41463cc6703</citedby><cites>FETCH-LOGICAL-c476t-8d3025a9ad77025fb9fbec2c539e8d2532505ffc60965ff984abfd41463cc6703</cites><orcidid>0000-0001-8908-1684 ; 0000-0001-6687-5393</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32469606$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kuppen, Malou Cp</creatorcontrib><creatorcontrib>Westgeest, Hans M</creatorcontrib><creatorcontrib>van der Doelen, Maarten J</creatorcontrib><creatorcontrib>van den Eertwegh, Alphonsus Jm</creatorcontrib><creatorcontrib>Coenen, Jules Llm</creatorcontrib><creatorcontrib>Aben, Katja Kh</creatorcontrib><creatorcontrib>van den Bergh, Alphons Cm</creatorcontrib><creatorcontrib>Bergman, Andries M</creatorcontrib><creatorcontrib>den Bosch, Joan van</creatorcontrib><creatorcontrib>Celik, Filiz</creatorcontrib><creatorcontrib>Hendriks, Mathijs P</creatorcontrib><creatorcontrib>Lavalaye, Jules</creatorcontrib><creatorcontrib>der Meer, Saskia van</creatorcontrib><creatorcontrib>Polee, Marco B</creatorcontrib><creatorcontrib>Somford, Diederik M</creatorcontrib><creatorcontrib>van Oort, Inge M</creatorcontrib><creatorcontrib>Uyl-de Groot, Carin A</creatorcontrib><creatorcontrib>Gerritsen, Winald R</creatorcontrib><title>Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity.
: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223.
Out of 285 patients, 49% received Ra-223 in line ≥3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line ≥3 (HR: 3.267; 95% CI: 1.689–6.317; p < 0.01) remained associated with worse OS.
: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014–2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Bone Neoplasms - metabolism</subject><subject>Bone Neoplasms - radiotherapy</subject><subject>Bone Neoplasms - secondary</subject><subject>Cancer therapies</subject><subject>Databases, Factual</subject><subject>Drug Administration Schedule</subject><subject>Hemoglobin</subject><subject>Humans</subject><subject>Lymphatic system</subject><subject>Male</subject><subject>Metastasis</subject><subject>metastatic castration-resistant prostate cancer</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms, Castration-Resistant - metabolism</subject><subject>Prostatic Neoplasms, Castration-Resistant - pathology</subject><subject>Prostatic Neoplasms, Castration-Resistant - radiotherapy</subject><subject>Radioisotopes - administration & dosage</subject><subject>Radium - administration & dosage</subject><subject>radium-223</subject><subject>real-world outcomes</subject><subject>Retrospective Studies</subject><subject>sequencing</subject><subject>skeletal-related events</subject><subject>survival</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kE1rHSEUhqW0NB_tstsidNONqV-j4zKEtAkEAqFdW68eqWFmTHSG0H_fc7lJF4Wuzqvn8agPIR8EP5NS2C-5LkxyyRnnyr0ix8JqzUbFxWvM2jpmjNNH5KT3e861VQN_S46U1MYZbo7JzzsIE3uqbUq0bmusM3RaM20hlW1mUiqaSvw11VYS0FwbnWENfQ1riTRiaJjqQhv0grvLSh9a3bcBu0uE9o68yWHq8P65npIfXy-_X1yxm9tv1xfnNyxqa1Y2JsXlEFxI1mLIO5d3EGUclIMxyUHJgQ85R8OdwepGHXY5aaGNitFYrk7J58NcvP9xg776ufQI0xQWqFv3UvNROCkHieinf9D7urUFX4eUVVrbUQik2IGK-KHeIPuHVubQfnvB_V69R_V-r97v1SP_8Xnqtpsh_aVfXCPgDkDe1g19xQIoyB9WeKLEssB_hv8Byd2SyQ</recordid><startdate>20200701</startdate><enddate>20200701</enddate><creator>Kuppen, Malou Cp</creator><creator>Westgeest, Hans M</creator><creator>van der Doelen, Maarten J</creator><creator>van den Eertwegh, Alphonsus Jm</creator><creator>Coenen, Jules Llm</creator><creator>Aben, Katja Kh</creator><creator>van den Bergh, Alphons Cm</creator><creator>Bergman, Andries M</creator><creator>den Bosch, Joan van</creator><creator>Celik, Filiz</creator><creator>Hendriks, Mathijs P</creator><creator>Lavalaye, Jules</creator><creator>der Meer, Saskia van</creator><creator>Polee, Marco B</creator><creator>Somford, Diederik M</creator><creator>van Oort, Inge M</creator><creator>Uyl-de Groot, Carin A</creator><creator>Gerritsen, Winald R</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8908-1684</orcidid><orcidid>https://orcid.org/0000-0001-6687-5393</orcidid></search><sort><creationdate>20200701</creationdate><title>Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer</title><author>Kuppen, Malou Cp ; Westgeest, Hans M ; van der Doelen, Maarten J ; van den Eertwegh, Alphonsus Jm ; Coenen, Jules Llm ; Aben, Katja Kh ; van den Bergh, Alphons Cm ; Bergman, Andries M ; den Bosch, Joan van ; Celik, Filiz ; Hendriks, Mathijs P ; Lavalaye, Jules ; der Meer, Saskia van ; Polee, Marco B ; Somford, Diederik M ; van Oort, Inge M ; Uyl-de Groot, Carin A ; Gerritsen, Winald R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c476t-8d3025a9ad77025fb9fbec2c539e8d2532505ffc60965ff984abfd41463cc6703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Bone Neoplasms - metabolism</topic><topic>Bone Neoplasms - radiotherapy</topic><topic>Bone Neoplasms - secondary</topic><topic>Cancer therapies</topic><topic>Databases, Factual</topic><topic>Drug Administration Schedule</topic><topic>Hemoglobin</topic><topic>Humans</topic><topic>Lymphatic system</topic><topic>Male</topic><topic>Metastasis</topic><topic>metastatic castration-resistant prostate cancer</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms, Castration-Resistant - metabolism</topic><topic>Prostatic Neoplasms, Castration-Resistant - pathology</topic><topic>Prostatic Neoplasms, Castration-Resistant - radiotherapy</topic><topic>Radioisotopes - administration & dosage</topic><topic>Radium - administration & dosage</topic><topic>radium-223</topic><topic>real-world outcomes</topic><topic>Retrospective Studies</topic><topic>sequencing</topic><topic>skeletal-related events</topic><topic>survival</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kuppen, Malou Cp</creatorcontrib><creatorcontrib>Westgeest, Hans M</creatorcontrib><creatorcontrib>van der Doelen, Maarten J</creatorcontrib><creatorcontrib>van den Eertwegh, Alphonsus Jm</creatorcontrib><creatorcontrib>Coenen, Jules Llm</creatorcontrib><creatorcontrib>Aben, Katja Kh</creatorcontrib><creatorcontrib>van den Bergh, Alphons Cm</creatorcontrib><creatorcontrib>Bergman, Andries M</creatorcontrib><creatorcontrib>den Bosch, Joan van</creatorcontrib><creatorcontrib>Celik, Filiz</creatorcontrib><creatorcontrib>Hendriks, Mathijs P</creatorcontrib><creatorcontrib>Lavalaye, Jules</creatorcontrib><creatorcontrib>der Meer, Saskia van</creatorcontrib><creatorcontrib>Polee, Marco B</creatorcontrib><creatorcontrib>Somford, Diederik M</creatorcontrib><creatorcontrib>van Oort, Inge M</creatorcontrib><creatorcontrib>Uyl-de Groot, Carin A</creatorcontrib><creatorcontrib>Gerritsen, Winald R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kuppen, Malou Cp</au><au>Westgeest, Hans M</au><au>van der Doelen, Maarten J</au><au>van den Eertwegh, Alphonsus Jm</au><au>Coenen, Jules Llm</au><au>Aben, Katja Kh</au><au>van den Bergh, Alphons Cm</au><au>Bergman, Andries M</au><au>den Bosch, Joan van</au><au>Celik, Filiz</au><au>Hendriks, Mathijs P</au><au>Lavalaye, Jules</au><au>der Meer, Saskia van</au><au>Polee, Marco B</au><au>Somford, Diederik M</au><au>van Oort, Inge M</au><au>Uyl-de Groot, Carin A</au><au>Gerritsen, Winald R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2020-07-01</date><risdate>2020</risdate><volume>16</volume><issue>19</issue><spage>1371</spage><epage>1384</epage><pages>1371-1384</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity.
: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223.
Out of 285 patients, 49% received Ra-223 in line ≥3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line ≥3 (HR: 3.267; 95% CI: 1.689–6.317; p < 0.01) remained associated with worse OS.
: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014–2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>32469606</pmid><doi>10.2217/fon-2020-0039</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0001-8908-1684</orcidid><orcidid>https://orcid.org/0000-0001-6687-5393</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future oncology (London, England), 2020-07, Vol.16 (19), p.1371-1384 |
| issn | 1479-6694 1744-8301 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2408192252 |
| source | MEDLINE; PubMed Central |
| subjects | Aged Aged, 80 and over Antineoplastic Agents - administration & dosage Bone Neoplasms - metabolism Bone Neoplasms - radiotherapy Bone Neoplasms - secondary Cancer therapies Databases, Factual Drug Administration Schedule Hemoglobin Humans Lymphatic system Male Metastasis metastatic castration-resistant prostate cancer Middle Aged Patients Prostate cancer Prostatic Neoplasms, Castration-Resistant - metabolism Prostatic Neoplasms, Castration-Resistant - pathology Prostatic Neoplasms, Castration-Resistant - radiotherapy Radioisotopes - administration & dosage Radium - administration & dosage radium-223 real-world outcomes Retrospective Studies sequencing skeletal-related events survival Survival Rate Treatment Outcome |
| title | Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T04%3A06%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real-world%20outcomes%20of%20radium-223%20dichloride%20for%20metastatic%20castration%20resistant%20prostate%20cancer&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Kuppen,%20Malou%20Cp&rft.date=2020-07-01&rft.volume=16&rft.issue=19&rft.spage=1371&rft.epage=1384&rft.pages=1371-1384&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon-2020-0039&rft_dat=%3Cproquest_cross%3E2408192252%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2473447811&rft_id=info:pmid/32469606&rfr_iscdi=true |